Stereotactic body radiotherapy for multisite extracranial oligometastases
Top Cited Papers
- 21 October 2011
- Vol. 118 (11), 2962-2970
- https://doi.org/10.1002/cncr.26611
Abstract
A subset of patients with metastatic cancer in limited organs may benefit from metastasis‐directed therapy. The authors investigated whether patients with limited metastases could be safely treated with metastasis‐directed radiotherapy. Patients with 1 to 5 metastatic cancer sites with a life expectancy of >3 months received escalating stereotactic body radiotherapy (SBRT) doses to all known cancer sites. Patients were followed radiographically with CT scans of the chest, abdomen, and pelvis and metabolically with fluorodeoxyglucose‐positron emission tomography, 1 month after treatment, and then every 3 months. Acute toxicities were scored using the National Cancer Institute's Common Terminology Criteria for Adverse Events version 3.0, and late toxicities were scored using the Radiation Therapy Oncology Group late toxicity scoring system. Sixty‐one patients with 113 metastases were enrolled from November 2004 to November 2009 on a prospective radiation dose escalation study. Median follow‐up was 20.9 months. Patients tolerated treatment well; the maximal tolerated dose was not reached in any cohort. Eleven patients (18.3%) have not progressed. One and 2‐year progression‐free survival are 33.3% (95% confidence interval [CI], 22.8‐46.1) and 22.0% (95% CI, 12.8‐34.4); 1‐year and 2‐year overall survival are 81.5% (95% CI, 71.1‐91.1) and 56.7% (95% CI, 43.9‐68.9). Seventy‐two percent of patients whose tumors progressed did so in limited (1‐3) metastatic sites. Patients with 1 to 5 metastases can be safely treated to multiple body sites and may benefit from SBRT. Further investigation should focus on patient selection. Cancer 2011;. © 2011 American Cancer Society.Keywords
This publication has 37 references indexed in Scilit:
- Radiation Pneumonitis After Hypofractionated Radiotherapy: Evaluation of the LQ(L) Model and Different Dose ParametersInternational Journal of Radiation Oncology*Biology*Physics, 2010
- Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung CancerJAMA, 2010
- Phase 1 study of concurrent sunitinib and image‐guided radiotherapy followed by maintenance sunitinib for patients with oligometastasesCancer, 2009
- Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung MetastasesJournal of Clinical Oncology, 2009
- Stereotactic radiotherapy of primary liver cancer and hepatic metastasesActa Oncologica, 2006
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialThe Lancet, 2004
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the BrainThe New England Journal of Medicine, 1990
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958